Biotech Drugs: More or Less Exclusivity?

This article in telegram.com brings up the much talked about debate in biologics in exactly how many years should makers of drugs by exempt from generic competition. Many pills are hard to re-produce but there are many drugs that are made of simple chemicals and are easy to replicate. Congress is trying to approve legislation now that would allow the FDA to approve generic versions of biologic drugs, and this could save consumers a lot of money in the long-run.

The Health Committee has approved for 12 years of exclusivity for the biotechnology industry, but the Obama administration seems to think that 7 years is a fair compromise? Do you agree with the Obama administration?

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |